<DOC>
	<DOCNO>NCT01842516</DOCNO>
	<brief_summary>Primary - To investigate safety tolerability LCB01-0371 multiple oral dose - To investigate pharmacokinetic characteristic LCB01-0371 multiple oral dose healthy male subject - To investigate safety LCB01-0371 multiple oral dose healthy male subject</brief_summary>
	<brief_title>Multiple Ascending Dose Study LCB01-0371</brief_title>
	<detailed_description>- To investigate PK characteristic LCB01-0371 multiple oral dose - To investigate safety tolerability LCB01-0371 multiple oral dose</detailed_description>
	<criteria>1 . Health Male 20 45 year age time screen subject body mass index ( BMI ) 19 27 2 . Medically healthy clinically significant screen result Physical examination , xray , 12 lead ECG , Laboratory test 3 . Able donate blood study period follow visit . 4 . Agree continue use reliable method birth control 60 day study completion . 5 . Capable give write informed consent Able understand comply protocol requirement , instruction protocolstated restriction . 1 . History liver , kidney , respiratory , musculoskeletal , endocrinologic , neuropsychiatric , hematooncologic , cardiovascular problem ( ) . 2 . History gastrointestinal problem affect absorption within 6 month screen 3 . History hypersensitivity clinically significant adverse drug reaction ( ) LCB010371 , class study drug ( linezolid ) , drug include aspirin antibiotic . 4 . History drug abuse positive result urine drug screen test amphetamine , methamphetamine , barbiturate , cocaine , opiate , benzodiazepine , cannabinoid , methadone , etc .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>